louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04402099: Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020
Official title: Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer
Lead sponsor: Collège des Pneumologues des Hôpitaux Généraux
Sponsor class: OTHER
First posted: 2020-05-26
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary Lung Cancer histologically proven between January 1st and December 31st, 2020

Brief summary: Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade.

Primary endpoint:

Estimate 1-year- and 5-year-mortality rates in patients with PLC.

Secondary endpoints:

* Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
* Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies
* Estimate prognostic factors
* Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies
* Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\*
* Follow-up by a lung specialist at a General Hospital
* Oral informed consent \* date of collected sample

Exclusion Criteria:

* Age \< 18 years
* Secondary lung cancer
* Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
* Previous enrolment in the study
* Freedom deprived patient following a legal or administrative decision
* Patient unable to give his(her) consent

Primary outcomes:
measure: Estimate 1-year mortality rates in patients with PLC.
timeFrame: 1 year
measure: Estimate 5-year mortality rates in patients with PLC.
timeFrame: 5 years
Secondary outcomes:
measure: Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
timeFrame: 1 year
measure: Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies
timeFrame: 1 year
Other outcomes:
Locations:
city: Paris
country: France
facility: Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College)
Study officials:
References:
Clinical trial NCT01786499: The Effect of Relaxation Response on Provider Burnout
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Burnout
Resilience
Perceived Stress
Keywords: Burnout
Stress
Provider
Relaxation Response
Lead sponsor: Allina Health System
Sponsor class: OTHER
First posted: 2013-02-08
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Hypothesis: Relaxation Response training is an effective intervention in reducing the prevalence and severity of burnout and its components from baseline levels among physicians receiving the training intervention. The intervention is hypothesized to moderate the relationship between Areas of Worklife (AWS) and burnout by improving physician's ability to cope with the demands of their workplace. This increased coping ability is hypothesized to reduce burnout.

Physician practices are as unique as the individual practitioners and the environment in which they practice. Traditional instruction of relaxation or self-care techniques has required participants to travel to locations remote from the workplace. The time commitment required for this behavior is additive to the time required to learn the intervention and of itself may induce extra stress increasing the potential for burnout. This study proposes that bringing the intervention to the workplace will increase provider willingness to participate and diminish the stress introduced by deployment of the intervention. Since inpatient and outpatient medicine have different practice characteristics and demands on the time of the practitioners, this study will need to develop and test the logistics necessary to bring the training to the different physician populations.


Eligibility criteria: Inclusion Criteria:

* Providers at designated clinic and hospital

Exclusion Criteria:

-

Primary outcomes:
measure: Change in burnout expression in study population
timeFrame: Three months
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Allina Health
state: Minnesota
Study officials:
References:
citation: Benson H, Greenwood MM, Klemchuk H. The relaxation response: psychophysiologic aspects and clinical applications. Int J Psychiatry Med. 1975;6(1-2):87-98. doi: 10.2190/376W-E4MT-QM6Q-H0UM.
citation: Leiter, M. P., & Maslach, C. (2004). Areas of worklife: A structured approach to organizational predictors of job burnout. Research in Occupational Stress and Well being: Emotional and Physiological Processes and Positive Intervention Strategies, 3, 92-134.
Clinical trial NCT02589899: Monitoring of Needle-placement With Multiple Frequency Bioimpedance Monitoring
Official title: Monitoring of Needle-placement With Multiple Frequency Bioimpedance Monitoring
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Electric Impedance
Human
Hypodermic Needles
Tissues
Nerve
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2015-10-28
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: A novel algorithm for bioimpedance measurements to detect nerve tissue, and discriminate it from other tissue types has been developed in a porcine model, by analysing a complex impedance dataset based on multiple measurement frequencies. It must now be confirm that the previous results are applicable in humans. Measurements from 24 predefined needle positions will be obtained in 16 of the 32 volunteers that are included in the study (part A). A new algorithm to detect nerve tissue will be developed based on these measurement results. Further impedance algorithms will be developed for other tissue type. The efficacy of the algorithms (sensitivity and specificity) will be evaluated in the 16 following volunteers (part B).


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* American society of anaesthesiologists score (ASA) 1 or 2
* Volunteers that have given informed written consent

Exclusion Criteria:

* Volunteers that cannot cooperate for the examination
* Volunteers with neurologic disease, nerve- or vascular impairment
* ASA \> 2

Primary outcomes:
measure: Success in the identification of nerve tissue by the use of an algorithm based on a multiple frequency impedance measurement (MFIM) algorithm. The outcome is binary (success vs failure).
timeFrame: From day 1 up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
References:
citation: Kalvoy H, Sauter AR. Detection of intraneural needle-placement with multiple frequency bioimpedance monitoring: a novel method. J Clin Monit Comput. 2016 Apr;30(2):185-92. doi: 10.1007/s10877-015-9698-3. Epub 2015 Apr 23.
Clinical trial NCT06631599: Effects of Trainings on Physical Performance in Soccer Players
Official title: Effects of Different Trainings on Physical Performance in Amateur Soccer Players at Different Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Health
Sport
Soccer Performance
Soccer Training
Keywords: soccer
fitness
trainig
strength
speed
Lead sponsor: University School of Physical Education, Krakow, Poland
Sponsor class: OTHER
First posted: 2024-10-08
Enrollment: 30
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The main objective of study was to examine the effects of different trainings on physical performance in amateur soccer players at different age. Participants trained according to various training protocols aimed at improving their motor skills (strength, power, speed, efficiency). We searched for the most optimal protocol, i.e. one that most effectively improves the study of motor skills and fitness.


Eligibility criteria: Inclusion Criteria:

* healthy male soccer players
* amatour

Exclusion Criteria:

* any diseases
* injury

Primary outcomes:
measure: speed
timeFrame: after 4 weeks of training
measure: power
timeFrame: after 4 weeks of training
measure: force-velocity profile
timeFrame: after 4 weeks of training
Secondary outcomes:
Other outcomes:
Locations:
city: Tarnów
country: Poland
facility: Academy of Applied Sciences
state: Tarnow
Study officials:
References:
Clinical trial NCT00638599: Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer
Official title: Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube for Airway Management in Modified Radical Mastectomy on Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Breast Cancer
Keywords: Intubation, intratracheal
Homeostasis
Mastectomy, modified radical
Breast Neoplasms
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2008-03-19
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Airway management in anesthesia is critical to guarantee appropriate treatment of possible respiratory complications and successful operative practice. LMA® is an alternative to tracheal tube in some surgeries like as mastectomy on breast cancer. Given no need using muscular relaxants in mastectomy, the investigators hypothesized that LMA® would be a superior manner in airway management in radical modified mastectomy on breast cancer than the tracheal tube, and the LMA® might produce less influence on patients' circulatory homeostasis, and easier to be placed before operation.


Eligibility criteria: Inclusion Criteria:

* Chinese
* Diagnosed breast cancer
* Undergoing modified radical mastectomy
* Agreed to participate the study with informed contract.

Exclusion Criteria:

* Organic dysfunction
* Long-lasting post-anesthetic care unit(PACU) staying.

Primary outcomes:
measure: Circulatory Homeostasis
timeFrame: 15min prior to operation to 15min posterior to operation
Secondary outcomes:
measure: Airway pressure
timeFrame: 15min prior to operation to 15min posterior to operation
measure: Blood gas
timeFrame: 15min prior to operation to 15min posterior to operation
measure: Airway complications
timeFrame: Start of operation to 6h after operation
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Maternal and Child Health Care Hospital
state: Jiangsu
Study officials:
affiliation: Nanjing Medical University
name: XiaoFeng Shen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02104999: Technical Accuracy and Userfriendliness of a Point-Of-Care C Reactive Protein Device in a Nursing Home Setting
Official title: Technical Accuracy and Userfriendliness of a Point-Of-Care C Reactive Protein (CRP) Device in Comparison With Laboratory CRP Testing in Nursing Home Residents.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Older Adults
Ill Older Adults
Lead sponsor: KU Leuven
Sponsor class: OTHER
First posted: 2014-04-07
Enrollment: 99
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Study to test the technical accuracy and userfriendliness of a Point-of-care C Reactive Protein device (POC CRP device) in comparison with laboratory CRP testing in nursing home residents


Eligibility criteria: Inclusion Criteria:

* Older (65 years or older) nursing home residents

Exclusion Criteria:

* Residents not understanding Dutch

Primary outcomes:
measure: Technical accuracy
timeFrame: 2 month
Secondary outcomes:
measure: User-friendliness
timeFrame: 2 months
Other outcomes:
Locations:
city: Gent
country: Belgium
facility: Domino vzw
state: Oost-Vlaanderen
Study officials:
affiliation: KU Leuven
name: Frank Buntinx, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06974799: Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis
Official title: Evaluation of Metabolomic Biomarkers in Pulmonary Fibrosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Fibrosis
Keywords: Metabolomic
Pulmonary Fibrosis
Lead sponsor: University of Campania Luigi Vanvitelli
Sponsor class: OTHER
Collaborators: name: Ceinge - Biotecnologie Avanzate s.c. a r.l.
First posted: 2025-05-16
Enrollment: 59
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with a diagnosis of IPF or other fibrotising interstitial lung disease within 5 years

Brief summary: Pulmonary fibrosis (PF) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality of life limitation as well significant morbidity and mortality. The identification of reliable biomarkers able to help in early diagnosis and predict disease progression are crucial for improving patient life. Although many biomarkers have been proposed, there is no consensus on reliable markers for IPF. Alterations in fatty acid (FA) metabolism have drawn increasing attention in the IPF pathogenesis, but there is no consensus on the specific FA changes. Alterations in FA composition have been shown to promote pro-fibrotic traits in epithelial cells, fibroblasts, and myofibroblasts. However, while specific fatty acid (FA) alterations have been identified in the serum of IPF patients, no consensus exists on the exact changes for individual FAs


Eligibility criteria: Inclusion Criteria:

* Confirmed IPF diagnosis based on the 2018 ATS/ERS/JRS/ALAT guidelines \[PMID: 30168753\] or other fibrotising ILDs within the past five years,
* Age ≥ 40 years, 3) ability to provide informed consent.

Exclusion Criteria:

* A current diagnosis of asthma or chronic obstructive pulmonary disease (COPD), 2) an acute PF exacerbation within the past three months.
* Use of medications who may alter metabolomic biomarkers, ex. statins.

Primary outcomes:
measure: Fatty acids measurement
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: UOC Clinica Pneumologica L Vanvitelli
Study officials:
References:
Clinical trial NCT02389699: Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ
Official title: Comparison of the Efficacy of Intra-operative Radiation Therapy After Conserving Surgery With Post-operative Whole Breast Radiotherapy for Women With Ductal Carcinoma in Situ
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Neoplasms
Keywords: Intermediate and high grade ductal carcinoma in situ （DCIS）
Lead sponsor: Guangdong Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2015-03-17
Enrollment: 74
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.The clinical trial is conducting to compare the effectiveness of radiation therapy during surgery and whole-breast radiation therapy in treating women who have undergone breast-conversing surgery for Intermediate or high grade ductal carcinoma in situ breast cancer.


Eligibility criteria: Inclusion Criteria:

* Tumor diameter \< 5 cm
* Intermediate or high grade ductal carcinoma in situ
* Informed consent

Exclusion Criteria:

* No informed consent
* Tumor size \> 3,5 cm
* Low grade ductal carcinoma in situ
* Invasive carcinoma
* No indication for a boost

Primary outcomes:
measure: ipsilateral breast tumor recurrence rate after surgery within five years
timeFrame: Within 5 years after surgery
measure: Disease free survival after surgery within five years
timeFrame: Within 5 years after surgery
Secondary outcomes:
measure: Overall survival after surgery within ten years
timeFrame: Within ten years after surgery
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong Academy of Medical Sciences
state: Guangdong
Study officials:
affiliation: Guangdong Academy of Medical Sciences
name: Liao Ning, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02349399: Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases
Official title: Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acne Vulgaris
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2015-01-28
Enrollment: 26065
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who are new users of CPA/EE in 2011/2012 and in 2014

Brief summary: The study objectives are to characterize new users of Cyproterone Acetate / Ethinylestradiol (CPA/EE) in 2011/2012 and in 2014 according to demographics, treatment characteristics, previous diagnosis of acne, hirsutism or other hyperandrogenic conditions, previous acne treatment and (concomitant) use of hormonal contraceptives identified in Healthcare Databases in the UK (THIN), the Netherlands (PHARMO) and Italy (HSD).


Eligibility criteria: Inclusion Criteria:

* The study population will include all female patients registered in the investigated healthcare databases receiving CPA/EE in 2011 or 2012 (first run) or 2014 (second run), without a prescription of CPA/EE in the year prior to index date. Only patients with recorded history in the database of ≥ 365 days prior to index date will be included in the study.

Exclusion Criteria:

* \<365 days recorded history in the database prior to index date
* a prescription of CPA/EE in the year prior to index date

Primary outcomes:
measure: Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Acne
timeFrame: up to 12 months
measure: Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Hirsutism
timeFrame: up to 12 months
measure: Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of other Hyperandrogenic Conditions (e.g. androgenic alopecia, seborrhea, polycystic ovary syndrome)
timeFrame: up to 12 months
Secondary outcomes:
measure: Determination of previous acne treatments (prescription drugs only) of Diane-35 (or generics) users with a previous diagnosis of acne.
timeFrame: up to 12 months
measure: Proportion (%) of new Diane-35 (or generics) users, who have concomitant prescriptions of other combined oral contraceptives
timeFrame: up to 12 months
Other outcomes:
Locations:
city: Many locations
country: Italy
city: Many locations
country: Netherlands
city: Many Locations
country: United Kingdom
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02579499: Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease
Official title: Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease: a Randomized Comparison Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Coronary Artery Diseasse
Keywords: Coronary artery disease
LDL choelsterol
Statin
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-10-19
Enrollment: 4400
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare clinical safety \& efficacy of fixed-high potent statin therapy (according to 2013 ACC/AHA guideline) vs. targeted LDL-C goal statin therapy (LDL\<70mg/dL) for secondary prevention. Total 4400 patients with coronary artery disease patients requiring statin treatment were categorized fixed high-potent statin group and targeted LDL-C group. The investigators will compare primary endpoint (major adverse cardiac and cerebrovascular event (MACCE)) and secondary endpoint (1. New onset diabetes mellitus after randomization, 2. Hospitalization due to heart failure, 3. Deep vein thrombosis or Pulmonary thromboembolism, 4. Percutaneous trans-luminal angioplasty on peripheral artery obstructive disease, 5. Aortic intervention or operation, 6. ESRD with renal replacement therapy).


Eligibility criteria: Inclusion Criteria:

* Patients ≥ 19 years old
* Patients clinically diagnosed with coronary artery disease including stable angina, unstable angina, acute non-ST elevation myocardial infarction and acute ST elevation myocardial infarction
* Patients with signed informed consent

Exclusion Criteria:

* Pregnant women or women with potential childbearing
* Patients severe adverse events or hypersensitive to statin or patients with multi-drug allergy.
* Who had received drug that have a drug interaction with statin (strong inhibitor of cytochrome p-450 3A4 or 2C9)
* Patients with risk factors for myopathy with hereditary muscle disorder, hypothyroidism, alcohol use disorder, severe hepatic dysfunction (3 times normal reference values) or rhabdomyolysis
* Life expectancy \< 3 years
* Patient with who can not be followed up for more than 1 year
* Patients who cannot understand or read the consent form

Primary outcomes:
measure: Major adverse cardiac and cerebrovascular events (MACCE)
timeFrame: 3 years
Secondary outcomes:
measure: numer of other adverse clinical events
timeFrame: 3 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine
Study officials:
affiliation: Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine
name: MYEONG-KI HONG, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: